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ABSTRACT
Biomimetic scaffolds are extremely versatile in terms of chemical composition and physical properties,
which can be deﬁned to accomplish speciﬁc applications. One property that can be added is the pro-
duction/release of bioactive soluble factors, either directly from the biomaterial, or from cells embed-
ded within the biomaterial. We reasoned that pursuing this strategy would be appropriate to setup a
cell-based therapy for RANKL-deﬁcient Autosomal Recessive Osteopetrosis, a very rare skeletal genetic
disease in which lack of the essential osteoclastogenic factor RANKL impedes osteoclast formation. The
exogenously administered RANKL cytokine is effective in achieving osteoclast formation and function
in vitro and in vivo, thus, we produced murine Rankl−/− MSCs overexpressing human soluble RANKL
(hsRL) following lentiviral transduction (LVhsRL). Here, we described a three-dimensional (3D) culture
system based on a Magnesium-doped hydroxyapatite/collagen I (MgHA/Col) biocompatible scaffold
closely reproducing bone physicochemical properties. MgHA/Col-seeded murine MSCs showed
improved properties, as compared to two-dimensional (2D) culture, in terms of proliferation and hsRL
production, with respect to LVhsRL-transduced cells. When implanted subcutaneously in Rankl−/− mice,
these cell constructs were well tolerated, colonized by host cells, and intensely vascularized. Of note, in
the bone of Rankl−/− mice that carried scaffolds with either WT or LVhsRL-transduced Rankl−/− MSCs,
we speciﬁcally observed formation of TRAP+ cells, likely due to sRL released from the scaffolds into cir-
culation. Thus, our strategy proved to have the potential to elicit an effect on the bone; further work
is required to maximize these beneﬁts and achieve improvements of the skeletal pathology in the trea-
ted Rankl−/− mice. STEM CELLS TRANSLATIONAL MEDICINE 2018
SIGNIFICANCE STATEMENT
RANKL-deﬁcient Autosomal Recessive Osteopetrosis is a very rare skeletal genetic disease in which
lack of the essential osteoclastogenic factor RANKL impedes osteoclast formation and bone
resorption, and causes extremely high bone density and secondary hematological and neurological
defects. At present, there is no cure for this disease. Here we demonstrated that RANKL-releasing
MSC-seeded biomimetic constructs implanted subcutaneously in Rankl−/− mice served as a source
of the missing cytokine and restored the formation of TRAP+ cells in bone, thus providing proof of
principle of the capacity of this approach to support cell differentiation towards the osteoclast lin-
eage in vivo. Implementation of the experimental setting by means of recent biotechnological
tools will increase the effectiveness of this strategy on the bone compartment.
INTRODUCTION
Over the last 15 years a great variety of biomi-
metic scaffolds, rationally designed devices with
speciﬁc physicochemical properties, conceived
to be seeded with cells, and used in vivo to
elicit or replace a missing function that cannot
be promptly restored by cells only, have been
developed [1]. In the bone ﬁeld, biomimetic
scaffolds are exploited for their osteoinductive
and osteoconductive properties; in basic studies,
they constitute a tool for evaluating osteogenic
potential of Mesenchymal Stromal Cells (MSCs)
from different tissues in ectopic bone formation
assays [2]. In translational studies, a range of
strategies for tissue engineering have been
implemented; in the majority of cases, bone-like
scaffolds support and induce bone regeneration
to replace areas of bone loss in large defects or
at load-bearing sites [3]. Biomaterials may also
serve as a source of bioactive soluble factors;
these may be either incorporated in the scaffold
during its production and released from there in
speciﬁc environmental conditions, or secreted
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by cells seeded on these three-dimensional (3D) struc-
tures [4, 5].
Our work intended to evaluate this latter application in the
context of Receptor Activator of Nuclear Factor k B Ligand-
deﬁcient Autosomal Recessive Osteopetrosis (RANKL-ARO), a rare
genetic skeletal disease in which lack of production of the essential
osteoclastogenic molecule RANKL by cells of the stromal compart-
ment in bone hinders osteoclast formation and bone resorption.
This leads to extremely high bone density and secondary hemato-
logical and neurological defects, which further compromise the
clinical picture, hence threatening the patients’ survival [6]. At vari-
ance with other known forms of ARO, in which the defect is cell
autonomous and early Hematopoietic Stem Cell Transplantation
(HSCT) is an effective cure, in RANKL-ARO the osteoclast defect is
not cell-autonomous, thus it cannot be rescued by HSCT [7, 8].
Thus, deﬁning a cure for RANKL-ARO is currently an unmet medi-
cal need, whose solution is unfairly complicated owing to the
extreme rarity of these patients.
Thanks to the availability of a mouse model (Rankl knock-
out, Rankl−/−) closely resembling the human disease, and to the
biological activity in vivo of soluble RANKL, two different tar-
geted therapeutic approaches have been evaluated at a preclini-
cal level: a pharmacological and a cell-based one [9, 10]. The
former consisted of the exogenous administration of soluble
recombinant RANKL to Rankl−/− mice; in our work, we evaluated
different treatment schedules and identiﬁed a speciﬁc protocol
able to correct the bone pathology [9]. As an alternative way to
provide the defective cytokine, Cappariello and colleagues
assembled diffusion chambers containing osteoblasts seeded on
a matrix metalloprotease 14 (MMP14)-functionalized scaffold to
facilitate RANKL shedding from the cell membrane, and
implanted them in vivo [10]. This strategy overcame the major
limitation of the pharmacological approach, that is, the require-
ment for high quality (Good Manufacturing Practice, GMP-level)
recombinant RANKL for a thorough preclinical study; however, it
required invasive surgery to obtain sufﬁcient RANKL release as
compared to in vivo cytokine administration.
Based on the nature of the defect in RANKL-ARO, here we
devised an approach based on Mesenchymal Stromal Cells (MSCs),
multipotent stromal cells characterized by in vitro plastic adher-
ence, colony-forming capacity, expression of a panel of surface
molecules, and ability to differentiate at least toward the osteo-
genic, adipogenic, and chondrogenic lineages [11]. In regenerative
medicine, they represent a valuable tool capable of restoring nor-
mal tissue function through the stimulation of repair mechanisms
by the host’s cells [12]. This mainly occurs via the production of a
wide range of trophic factors, also comprised of the RANKL cyto-
kine [3, 11, 13–15]. On this basis, MSCs are under evaluation for
cell therapy of a range of disorders, which could be combined with
gene delivery via viral vectors to elicit speciﬁc MSC properties [16].
Moreover, increasing evidence showed that MSC features
are strictly dependent on environmental, physical, mechanical,
and chemical characteristics, and this drove the engineering of
biomimetic scaffolds artiﬁcially reproducing selected natural
microenvironments [17].
Of note, we recently reported the generation of wild type
(WT) and Rankl−/− murine MSC lines, and, in the latter, the res-
toration of RANKL production and osteogenic capacity by trans-
duction with a lentiviral vector expressing human soluble
RANKL [13]. Based on the close resemblance of RANKL-defective
osteopetrosis in humans and mice, we envisage RANKL produc-
tion might be similarly reestablished in patient-derived cells.
Overall, these data provided the rationale for our novel
approach: we hypothesized that MSC-seeded scaffolds carrying
either WT or transduced cells, might serve as a factory of solu-
ble RANKL, and thus provide the cytokine in Rankl-deﬁcient
osteopetrosis to restore osteoclastogenesis. Here, we describe
the establishment of murine MSC 3D cultures on a bone bio-
mimetic scaffold and provide proof-of-principle that subcuta-
neous implantation of these scaffolds seeded with RANKL-
expressing MSCs in Rankl−/− mice restores formation of TRAP+
cells, bona ﬁde osteoclasts in the bone tissue.
MATERIALS AND METHODS
Cell Culture
The Human Embryonic Kidney 293 T (HEK293T) cell line was
purchased from ATCC and cultured in IMDM medium supple-
mented with 10% fetal bovine serum (FBS; both from GIBCO,
Grand Island, NY), 1% penicillin/streptomycin and 1% gluta-
mine (Lonza, Basel, Swizerland).
Bone marrow-derived mesenchymal stromal cells (MSCs)
were isolated, cultured, and characterized as previously
described from both WT and Rankl−/− mice [13]. Cells were
kept in a humidiﬁed 5% CO2 incubator at 37C.
Lentiviral Transduction
The third-generation bidirectional lentiviral vectors (LVhsRL
and mock) used for HEK293T and MSCs transduction have
been already described [13]. Brieﬂy, the IgK-chain leader secre-
tion signal followed by the extracellular region of human
RANKL (nucleotides 416-954, NM_003701) was inserted into
the #1074.1071.hPGK.GFP.WPRE.mhCMV.dNGFR.SV40PA plas-
mid backbone (gift of Prof Luigi Naldini, San Raffaele Telethon
Institute for Gene Therapy, Milan), according to standard pro-
tocols. The lentiviral vectors were produced following standard
procedures and in accordance with institutional and national
laws (notiﬁcation n. MI/IC/IMP2/12-003).
The day before transduction, HEK293T cells were plated at a
density of 104 cells/cm2 in 6-well plate. Lentiviral transduction was
performed in 1.0 ml culture medium at a multiplicity of infection
(MOI) ranging from 1 to 100, in the presence of 8 μg/ml Polybrene
(Sigma-Aldrich, Saint Louis, MO); untransduced cells were treated
with Polybrene only as control. After 16 hours, the medium was
replaced with fresh culture medium. Transduced cells expressing
GFP were analyzed by ﬂow cytometry (FACSCantoII, BD Bioscience,
Eysins, Switzerland) to assess GFP ﬂuorescence. HEK293T cell via-
bility was evaluated through the dye exclusion test with Trypan
blue and by MTT Test, following standard procedures. Two weeks
after transduction, vector copy number (VCN) was determined by
qPCR as previously described [18].
Rankl−/− MSCs were transduced with either LVhsRL or
mock lentiviral vector at 20 MOI, as previously described, and
maintained in MSC complete Mesencult medium (Stemcell
Technologies, Vancouver, BC) [13].
RANKL Protein Analysis
Total protein extraction, gel electrophoresis, transfer, and visu-
alization were performed according to standard Western blot-
ting procedures. Brieﬂy, cell lysis was done in RIPA buffer and
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proteins were quantiﬁed using the DC Protein Assay Kit II
(Biorad, Berkeley, CA) following the manufacturer’s instruc-
tions, on a Synergy H4 instrument (BioTek Instruments, Inc.,
Winooski, VT). Twenty-ﬁve micrograms of protein extracts
were separated on a 10% Sodium Dodecyl Sulfate Polyacryl-
amide Gel Electrophoresis (SDS-PAGE) and transferred to a
nitrocellulose membrane. This was incubated with human
RANKL monoclonal antibody (Alexis Corporation, Lausen, Swit-
zerland), diluted 1:1,000 in 5% milk solution, for 2 hours at
room temperature, then washed, probed with a secondary
antibody conjugated with HRP and developed using the Immo-
bilon Western kit (Millipore, Darmstadt, Germany). Images
were acquired using the ChemiDoc MP Imaging System
equipped with Image Lab Software (Biorad).
In Vitro Osteoclastogenesis and Resorption Assay
Conditioned culture medium (CM) from HEK293T cells trans-
duced with either LVhsRL or the mock vector at 20 MOI under-
went protein enrichment by Vivaspin column 10 MWCO
(Sartorius, Goettingen, Germany) ultraﬁltration according to
the manufacturer’s instructions, to obtain a ×50 concentrated
CM with a ﬁnal concentration of about 2 ng/ml hsRL.
In vitro osteoclastogenesis was induced in human PBMCs
obtained from buffy coat of healthy donors by Ficoll separa-
tion or in murine WT and Rankl−/− murine splenocytes. Brieﬂy,
4 × 105 cells/well were cultured in 96-well plate in αMEM
medium (Sigma-Aldrich) supplemented with 10% FBS, 1% peni-
cillin/streptomycin, and 1% glutamine in the presence of
25 ng/ml M-CSF, 5 ng/ml human TGFβ1 (both from Peprotech,
London, UK), 1 μM Dexamethasone (Sigma-Aldrich) and with
or without 100 μl/ml of either CM for 6 or 12 days (for murine
and human cells, respectively). Mature osteoclasts were
stained using the Tartrate Resistant Acid Phosphatase (TRAP)
Kit (Sigma-Aldrich) following the manufacturer’s instruction.
The same culture conditions were used to perform osteo-
clastogenesis on dentin discs (Immunodiagnostic Systems, Ltd.,
Scottsdale, AZ) to evaluate osteoclast resorption activity. After
3 weeks, dentin discs were rinsed with water, scraped to
remove attached cells, stained with 1% toluidine blue solution
for 3 minutes, and then washed with water to visualize resorp-
tion pits. Images were acquired on an EVOS XL Inverted Micro-
scope (Thermo Fisher Scientiﬁc, Waltham, MA) for both TRAP+
mature osteoclasts and toluidine blue stained dentin discs.
MgHA/Col Scaffold Synthesis
Equine tendon derived type I collagen, 1 wt.% in aqueous acetic
buffered solution (pH 3.5), was purchased from Opocrin SpA
(Modena, Italy). Phosphoric acid (H3PO4, 85 wt.%), calcium hydrox-
ide (Ca(OH)2, 95 wt.%), magnesium chloride hexahydrate
(MgCl26H2O, 99 wt.%), and 1,4-butanediol diglycidyl ether
(BDDGE, 95 wt.%) were purchased from Sigma Aldrich. Phosphate
buffer saline (PBS, pH 7.4) was supplied by EuroClone (Milan, Italy).
Brieﬂy, 100 g of collagen gel were dissolved into a 0.04 M
phosphoric acid solution, while 0.235 g of MgCl26H2O were
added to a 0.07 M basic calcium suspension [19, 20]. The acid
collagen slurry was added drop-wise into the basic calcium
and magnesium suspension, leading to the formation of Mg-
doped apatite nanocrystals uniformly distributed in the colla-
gen matrix. After 2 hours at room temperature, the hybrid
slurry was washed three times in distilled water and ﬁltered to
remove free ions. The cross-linking reaction was carried out in
the presence of 20 ml of 1 g/L of BDDGE solution for 24 hours
at room temperature, followed by 24 hours at 4C [21, 22].
Afterward, the cross-linking solution was removed and the
hybrid composite was washed three times with distilled water
before pouring it into polystyrene 96-well plate. Porous 3D-
hybrid scaffolds were obtained by freezing the collagen hydrogel
at −40C and drying it at 25C (5 Pascal, LIO 3000 PLT, Milan,
Italy) for 48 hours under a constant vacuum of 0.086 mbar.
Finally, the scaffolds were sterilized by gamma-irradiation.
Scanning Electron Microscopy (SEM)
Specimens were mounted onto aluminum stubs using black
carbon tapes and sputter coated with gold (Sputter Coater
Q150TES, Laughton, UK). The specimen surface and scaffold
microarchitecture were examined using high resolution SEM
(FEI, Quanta 200, Cambridge, UK) under a pressure of 0.1
mTorr at an accelerating voltage of 7 or 10 kV.
Structural Characterization of MgHA/Col
The total porosity was calculated by the gravimetric
(or density) method [23], according to the formula:
total porosity %ð Þ¼ 100− ρ
ρtheoretical
× 100
 
,
where ρ is the scaffold density determined with the equation:
ρ¼ W
π× D2
 2 ×H ,
in which W is the weight, D is the diameter, and H is the
height of the scaffold; and the theoretical density of the mate-
rial is calculated from the theoretical density and weight frac-
tion (XA, XB,…) of each reagent:
ρtheoretical ¼ ρtheoretical Að Þ × XA
 
+ ρtheoretical Bð Þ × XB
 
:
The macropores volume percentage was calculated by the
water squeezing method [24]. Brieﬂy, the scaffold was equilibrated
in deionized water for 1 hour and weighed (Mswollen), then
squeezed to remove the water ﬁlling the pores and weighed again
(Msqueezed). Macropores volume was calculated using the equation:
Macropores volume percentage¼ Mswollen −Msqueezedð Þ
Mswollen
× 100:
All the values were expressed as the mean  SEM (n = 3).
X-Ray Diffraction (XRD)
XRD patterns of the samples were recorded on a D8 Advance
diffractometer (Bruker, Karlsruhe, Germany) equipped with a
Lynx-eye position sensitive detector using Cu Kα radiation
(l = 1.54178 Å) generated at 40 kV and 40 mA. XRD spectra
were recorded in the 2θ range from 20 to 60 with a step size
(2θ) of 0.02 and a counting time of 0.5 seconds.
Fourier Transform Infrared Spectroscopy (FTIR)
FTIR spectra were collected on a Nicolet 380 spectrometer
(Thermo Fisher Scientiﬁc Inc.) with a resolution of 4 cm−1 by
accumulation of 64 scans covering the 4,000 to 400 cm−1
range, using the KBr pellet method.
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The pellets (13 mm ) were prepared by mixing 2 mg of
ground sample with 100 mg of KBr in a mortar and pressing.
Inductively Coupled Plasma Optical Emission
Spectrometry (ICP-OES)
Calcium, phosphate, and magnesium contents were deter-
mined by ICP-OES using a Liberty 200 spectrometer (Varian,
Palo Alto, CA). Twenty milligram of sample were dissolved in
50 ml of a 1 wt.% HNO3 solution prior to analysis.
Thermal Gravimetric Analysis (TGA)
The thermal properties and the ratio between collagen and
MgHA in the hybrid sample were measured using a simulta-
neous thermal analyzer STA 449/C Jupiter (Netzsch, Germany).
Simultaneous TGA was carried out on approximately 10 mg of
sample placed in alumina crucibles, and then brought from
room temperature to 1,200C at a heating rate of 10C/min
under an airﬂow of 1 ml/min.
Swelling and Degradation Tests
The scaffolds were soaked in PBS, pH 7.2 in the presence of
0.1% (wt/vol) NaN3 at 37
C. At speciﬁc time points, the sam-
ples were blotted with a piece of paper to remove surface
droplets. The swelling ratio (Qs) was evaluated using the fol-
lowing equation:
Qs¼Ws −Wd
Wd
,
where Ws is the weight of the swollen sample at a speciﬁc
time point and Wd the initial weight of the dried sample.
In the degradation test, the scaffolds were soaked as
above, then washed twice with milli-Q water, freeze-dried for
2 days and subsequently weighed. The degradation percentage
(D) was evaluated using the following equation:
D %ð Þ¼Wi −Wf
Wi
× 100,
where Wi is the initial weight of the dried sample and Wf the
weight of the freeze-dried sample at a speciﬁc time point.
Standardization of MSC 3D Culture
Sterile MgHA/Col scaffolds were incubated overnight at 37C
in the MSC conventional culture medium. The day after, the
scaffolds were placed in 48-well plate (1 scaffold/well).
LVhsRL-MSCs with 5 × 105 were suspended in 30 μl of stan-
dard culture medium and dropped onto each scaffold. Cell
attachment was allowed for 30 minutes at 37C and 5% CO2.
Subsequently, 1 ml of cell culture medium was added to the
cell-seeded 3D scaffold system to completely cover it. To eval-
uate cell morphology and behavior in 3D culture, we took
advantage of GFP expression by transduced MSC and collagen
autoﬂuorescence. Cell-seeded scaffold systems were formalin
ﬁxed at 24, 48, and 72 hours after seeding and analyzed by
confocal microscopy. Images were acquired with a laser-
scanning confocal microscope (FluoView FV1000, Olympus
Corp., Hamburg, Germany), with 405 and 488 nm wavelength
laser excitation for collagen and GFP+-MSC-transduced cell,
respectively. The resulting ﬂuorescence emissions were col-
lected in a wavelength range from 425 to 475 nm (for colla-
gen) and from 500 to 560 nm (for GFP+ MSC-transduced cell).
Images were acquired with a 10X UPLSAPO objective
(Olympus); then, processing, analysis, 3D stack reconstruction
and surface rendering were performed using Imaris ×64
7.6.5 software (Bitplane, Belfast, Ireland).
For the evaluation of MSC viability and human RANKL pro-
duction over time, cell-seeded scaffolds were maintained up to
6 days and the medium changed every 2 days; conventional 2D
culture of the same cells (5 × 105 cells in 6-well plate) was con-
comitantly performed as a control. For both 2D and 3D cultures,
at days 2, 4, and 6, cell viability of WT, mock-transduced, and
LVhsRL-transduced Rankl−/− MSCs was assessed through MTT
assay. hsRL levels were measured after 3 days of culture by
ELISA (PromoCell GmbH, Heidelberg, Germany) on the culture
medium collected from LVhsRL-transduced Rankl−/− MSCs.
In Vivo Implantation
All mouse experimental procedures were performed in accor-
dance with the Humanitas Institutional Animal Care and Use
Committee and with international laws (authorization
n.540/2017-PR). Rankl+/− mice were a kind gift of Prof. Yong-
won Choi (University of Pennsylvania, Philadelphia, PA) [25].
The colony was maintained in heterozygosis in a speciﬁc
pathogen-free facility; the litters were genotyped as described
[25] and Rankl−/− mice were fed a soft diet after weaning. The
study design comprised only Rankl−/− mice. In detail, 6 week old
Rankl−/− mice (both males and females) were randomly divided
in three groups: one was implanted with LVhsRL-transduced
MSC-seeded scaffolds, another with mock-transduced MSC-
seeded scaffolds and the last with WT MSC-seeded scaffold, as
controls. In each group, mice were implanted with either 1 or
2 scaffolds, which were prepared following a different protocol:
(a) 1 scaffold/mouse: seeding of 7 × 105 cells (WT MSC, or
mock-transduced or LVhsRL-transduced MSC) and implantation
after overnight culture at 37C, 5% CO2; (b) 2 scaffolds/mouse:
seeding of 1.5 × 106 cells/scaffold (WT MSC, or mock-
transduced or LVhsRL-transduced MSC), 3 days culture at 37C,
5% CO2 to allow cell penetration into the scaffold, and then
implantation. In both protocols, the yield of cell seeding was
calculated as a ratio between the amount of cells effectively
attached to the scaffold (inferred as the difference between the
number of seeded cells and that of cells left on the bottom of
the well) and those initially seeded.
For the surgery, Rankl−/− mice underwent deep anesthesia
(Ketamine/Xylazine) and were shaved on the back; then, under
sterile conditions the skin was incised over the shoulders and
a subcutaneous pouch was formed, in which the cell-seeded
scaffold(s) was (were) inserted. The incision was sewn up with
wire absorbable suture; then the mice were kept warm on a
special hotplate and singly housed, when they had sufﬁciently
recovered. After 8 weeks, mice were sacriﬁced by CO2 asphyxi-
ation; blood, scaffold systems, long bones, and soft tissues
were collected for serological and histological evaluations.
Histological Analysis
The harvested scaffolds were ﬁxed in 4% paraformaldehyde
(PFA) and decalciﬁed in ion exchange decal unit (Biocare Medi-
cal, Concord, CA), dehydrated and embedded in parafﬁn for
hematoxylin and eosin (H&E) staining and for immunohisto-
chemistry by using anti-GFP (Invitrogen Thermoﬁsher; 1:200),
anti-CD31 (R&D, Minneapolis, MN; 1:1,000), and anti-F4/80
(Biorad; 1:100) antibodies according to standard protocols.
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Bones were ﬁxed in 4% PFA for 48 hours, decalciﬁed in
14% EDTA solution for 2 weeks and parafﬁn-embedded for
TRAP staining with the Acid Phosphatase TRAP kit (Sigma-
Aldrich). TRAP+ cells were counted in at least two stained long
bone sections per animal. Digital images were acquired with
an Olympus XC50 camera mounted on a BX51 microscope
(Olympus), and analyzed with CellF Imaging software (Soft
Imaging System GmbH, Munster, Germany).
All other tissues were harvested, formalin-ﬁxed, and
parafﬁn-embedded for H&E staining.
hsRL Cytokine and Calcium Level Evaluation
The concentration of hsRL in the culture medium of trans-
duced and untransduced HEK293T cells and of 2D or 3D cul-
tured MSC was determined using the human sRANKL (total)
Enzyme Linked Immunosorbent Assay (ELISA) kit (PromoCell
GmbH, Heidelberg, Germany). Serum total calcium levels were
determined using a Ci16200 Architect Abbott instrument
(Abbott Park, Green Oaks, IL).
Statistical Analysis
Statistical analysis was performed using Mann–Whitney test or
t test when comparing two groups. One-way or Two-way Anova
with Tukey’s post-test were used for multiple comparisons
(GraphPad Prism 5.0, GraphPad Softwares Inc. La Jolla, CA). Sta-
tistical signiﬁcance was considered when p < .05 (*p < .05,
**p < .01, ***p < .001). All the experiments were performed at
least in triplicate. All data are presented as mean  SEM.
RESULTS
Validation of a Lentiviral Vector Expressing Human
Soluble RANKL
We recently produced a third generation bidirectional lentiviral
vector, expressing human soluble RANKL (LVhsRL), under the
minimal core element of the CMV promoter (mhCMV) and the
green ﬂuorescent protein (GFP) under the human PGK (hPGK)
promoter (Fig. 1A); the vector expressing only the GFP was used
as a control [13]. We utilized the HEK293T cell line as commonly
accepted for validation procedures [18, 26]. Namely, we trans-
duced HEK293T cells with increasing amount of lentiviral parti-
cles, from 1 to 100 MOI for both the LVhsRL and mock vector. In
both conditions, the fraction of transduced cells was directly pro-
portional to the used MOI up to MOI 20, and no signiﬁcant dif-
ference was found between MOI 20, 50 and 100, as assessed
through GFP ﬂuorescence by cytoﬂuorimetric analysis (Fig. 1B,
left plot); so the transduction efﬁciency of the two vectors was
comparable. Mean Fluorescence Intensity (MFI) of GFP+ cells was
comparable at MOI 1–20, and higher at MOI 50 and 100 with
both vectors (Fig. 1B, right plot), likely due to higher viral integra-
tion in these latter conditions. In addition, cell viability and
growth, measured through the MTT test at 24, 48 and 72 hours
posttransduction, inversely correlated to the used MOI, as
expected (Fig. 1C). At all the time points, RANKL concentration
was signiﬁcantly higher in the supernatant of LVhsRL-transduced
as compared to untransduced cells, as expected. In particular, in
a short timeframe (within 3 days after transduction), no differ-
ence was observed between 1, 5, and 10 MOI. At 20, 50, and
100 MOI RANKL production signiﬁcantly higher as compared to
lower MOIs at all the time points. At 48 and 72 hours after
transduction, cytokine levels were greatly reduced at MOI
50 and 100 (Fig. 1D), likely due to decreased cell viability at these
MOIs; no such effect was observed at MOI 20. Then, we selected
the conditions 10, 20, and 50 MOI for long-term culture (up to
12 days after transduction). In this period, cells of all experimen-
tal settings recovered as inferred by measuring RANKL produc-
tion, which was sustained and proportional to the used MOI, as
assessed both in the cells by Western blot and in the superna-
tant by ELISA assay (Fig. 1E). The achieved VCN was similar
between LVhsRL-transduced and mock-transduced cells, with
values of 4.56, 8.45, and 16.16 for cells transduced with the
LVhsRL vector at 10, 20, and 50 MOI, and 3.02, 4.74, and 16.58
for cells transduced with the mock vector at the same MOIs.
Overall, these results showed that the LVhsRL vector was
able to transduce effectively HEK293T cells and to achieve sus-
tained soluble RANKL production. In addition, based on these
data and foreseeing the usage of transduced cells shortly after
transduction, we reasoned that 20 MOI provided an optimal
balance between cell viability and RANKL production; there-
fore, the following experiments were performed at this MOI.
Functional Evaluation of the RANKL Cytokine Produced
by Transduced HEK293T Cells
To assess whether the RANKL cytokine expressed by the lenti-
viral vector was biologically active, we veriﬁed whether it was
capable of inducing osteoclast differentiation from mouse and
human precursor cells; in fact, human RANKL is known to be
effective on precursors from both species [27, 28]. In detail, the
conditioned media (CM) of LVhsRL-transduced HEK293T cells
(MOI 20) was used in a standard osteoclastogenesis assay in
place of the recombinant RANKL cytokine; the CM of mock-
transduced HEK293T cells was used in parallel, as a negative
control. In this regard, it is worth mentioning here that the
RANKL concentration in LVhsRL-transduced HEK293T superna-
tants was lower than that used in standard osteoclastogenesis
protocols (i.e., 37.13  0.8 pg/ml as compared to 20–100 ng/ml
[29, 30]). Therefore, the CM from both LVhsRL-transduced and
mock-transduced cells was concentrated by a factor of
50, achieving an hsRL concentration of 2.32  0.28 ng/ml in the
LVhsRL-CM, prior to application to the osteoclastogenesis assay.
Then, WT or Rankl−/− murine splenocytes and human
peripheral blood mononuclear cells (PBMCs) from a healthy
donor were cultured either on plastic or dentin discs in the
presence of M-CSF and with or without the concentrated
CM. At the end of the differentiation protocol, in the presence
of RANKL-containing CM, osteoclasts formed from both murine
and human precursor cells and resorbed dentin, as demon-
strated by TRAP and toluidine blue staining, respectively. On the
other hand, no differentiation was achieved in the presence of
the concentrated mock CM (Fig. 2). The most obvious explana-
tion to this result was that hsRL present in the LVhsRL CM
endowed this supernatant with a pro-osteoclastogenic capacity.
Overall, these data conﬁrmed that the RANKL cytokine
expressed by the lentiviral vector was functional in vitro.
Production of a 3D Biomimetic Scaffold
We recently reported on the generation and characterization of
murine bone marrow-derived WT and Rankl−/− MSCs, and the
transduction of these latter with LVhsRL and mock lentiviral vec-
tors [13]. In the framework of the present study, to favor MSC
survival and proliferation, and enhance their functional
www.StemCellsTM.com © 2018 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
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properties, we set up a 3D culture. In detail, we generated a
scaffold made of Magnesium-doped hydroxyapatite/collagen I
(MgHA/Col), which could ideally mimic the physicochemical
characteristics of the bone. The 3D hybrid composites were
synthetized through a biomineralization process allowing nucle-
ation of biomimetic HA nanoparticles on type I collagen ﬁbers
during their self-assembly guided by pH changes. SEM analysis
showed the porosity and the whole hybrid’s structure at low
magniﬁcations, and the formation of nanostructured and homo-
geneously distributed apatite nanocrystals aligned on collagen
ﬁbers, at high magniﬁcation (Fig. 3A). The assessment of the
porosity of the hybrid composite with two different methods
highlighted a total porosity close to 95% comprising nanopores
and micropores and about 60% of macropores suitable for cell
proliferation (Fig. 3B). TGA analysis revealed a weight ratio of
the MgHA/Col hybrid composite 60/40 (Fig. 3C), so very close
to the composition of the natural bone tissue [31]. FTIR spectra
of the hybrid composite MgHA/Col and of an hydroxyapatite
(HA) synthetized in the same condition and selected as refer-
ence material, revealed the presence of typical peaks of colla-
gen together with those of apatite in the biomineralized
material. In detail, the peaks at about 1,000 cm−1 and 600 cm−1
correspond to the apatite, while those between 1,300 cm−1 and
1,650 cm−1 correspond to the alpha-helical structure of collagen
at amide I, II, and III. In particular, the shift from 1,340 cm−1 to
1,337 cm−1 was because of the stretching of COOˉ groups of
collagen, indicating the active interaction of collagen functional
groups with the positively charged apatite crystals (Fig. 3D).
XRD analysis of the hybrid MgHA/Col and of the reference
HA showed the typical peaks of low crystalline apatites; how-
ever, the mineral phase synthetized through the biomineraliza-
tion process produced wider peaks. This indicated that the
presence of Mg2+ ions and the template and structural conﬁne-
ment action of collagen ﬁbers led to the formation of a less
crystalline and thus more biomimetic mineral phase (Fig. 3E).
ICP analysis conﬁrmed the presence of Magnesium in the
ﬁnal composite with evidence of a partial substitution of Cal-
cium with Magnesium in the apatite lattice. In particular, ICP
showed that about 70 wt.% of the initial nominal concentra-
tion of Mg2+ ions substituted Ca2+ in the apatite lattice, and
that the Ca/P ratio of the MgHA nucleated on collagen was in
the typical range of low crystalline apatite (1.45–1.60), as
expected (Fig. 3B). Finally, this material had high hydrophilicity
and very low-degradation rate, thanks to the stability
Figure 1. Validation of a lentiviral vector expressing human soluble RANKL (hsRL). (A) Schematic representation of the lentiviral vector
for the expression of hsRL. (B) Quantization of HEK293T cell transduction with the LVhsRL and mock vector at increasing MOI, expressed
as percentage of GFP+ cells (left) and as GFP mean ﬂuorescence intensity (MFI; right). (C) Evaluation of cell growth rate over time of
untransduced and transduced HEK293T cells, by MTT assay. (D) Quantization of hsRL production over time by untransduced and trans-
duced HEK293T cells, by ELISA assay on the corresponding supernatants. Only statistics between different time points of the same MOI is
indicated. (E) Quantization of hsRL in protein extracts (left) and in supernatants (right) of untransduced and transduced HEK293T cells
2 weeks after transduction. *p < .05; **p < .01, ***p < .001.
© 2018 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
STEM CELLS TRANSLATIONAL MEDICINE
6 MSC-Seeded Scaffolds for RANKL Delivery
conferred by the crosslinking action of BDDGE [20] (Fig. 3F,
3G). Overall, these properties made our scaffold particularly
suited for in vitro and in vivo experiments.
MSC Culture on MgHA/Col Scaffolds
As above explained, our strategy is based on the use of MSC.
Thus, we exploited WT and Rankl−/− MSC lines previously gen-
erated and afterward transduced at MOI 20 according to the
validation experiments [13]. For the present purpose, we ﬁrst
studied MSC behavior on the produced scaffolds in terms of
cell morphology and interactions, attachment to the collagen
ﬁbers and invasion. To this end, we took advantage of GFP
expression by transduced MSCs, on one hand, and of collagen
autoﬂuorescence, on the other. Initially, cells appeared to dis-
tribute on top of the scaffold, showing their typical “ﬁbroblast-
like” shape, to organize and ﬁrmly attach along the collagen
ﬁbers. As early as 48 hours after seeding, they had entered
the scaffold and begun to colonize it; in addition, cell prolifera-
tion and cell-to-cell contacts appeared to increase over time.
On the other hand, the scaffold itself was modiﬁed and remo-
deled over time by the invading cells (Fig. 4A).
Then, we compared cell proliferation in 2D versus 3D cul-
ture on the produced scaffold. At all time points, cell growth,
determined as fold increase as compared to day 0, was greater
in 3D than in 2D cultures, irrespective of the genotype, or vec-
tor used for transduction (Fig. 4B and Supporting Information
Table S1). Furthermore, the amount of cytokine produced by
the LVhsRL-transduced cells upon 3D culture was signiﬁcantly
higher as compared to the 2D setting (Fig. 4C); in contrast, the
RANKL cytokine was absent in mock-transduced Rankl−/− MSCs
culture medium, as expected ([13] and data not shown).
Overall, these data demonstrated that our MgHA/Col scaf-
fold was a good substrate for MSCs culture: seeded cells
adhered nicely and interacted with the provided support and
extensively colonized it; moreover, their viability was main-
tained and proliferation was increased over time. Thus, the
cytokine production was signiﬁcantly enhanced.
In Vivo Implantation
We already reported evidence showing that a similar cell-scaffold
construct was well tolerated and osteoinductive in immunodeﬁ-
cient mice [13]. Here, we veriﬁed the in vivo biocompatibility of
the cell-seeded MgHA/Col scaffold and the effect of lentivirally
mediated RANKL production in the Rankl−/− mouse. In detail,
Rankl−/− mice underwent subcutaneous implantation of a scaffold
seeded with 7 × 105 cells, which were either LVhsRL-transduced
or mock-transduced Rankl−/− MSCs or WT MSCs, as controls; the
seeding efﬁciency was about 90%. After surgery, the animals
were monitored for 2 months; in this timeframe, no sign of dis-
tress was apparent. At necropsy, the scaffold, long bones, spine,
and selected tissues were harvested and processed for histologi-
cal analysis. Hematoxilin-Eosin (H&E) staining of the scaffolds
showed that, irrespectively of the speciﬁc type of seeded cells,
they were well colonized by live cells and extensively vascular-
ized; the presence of vessels was conﬁrmed by immunostaining
for CD31 (Fig. 5A, left plots). This evidence supports the hypothe-
sis that soluble factors produced by the implanted MSCs, also
comprising the RANKL cytokine, could reach the general circula-
tion, thus possibly eliciting a biological effect. Of note, the cells
populating the scaffolds were at least in part of donor origin, as
demonstrated by GFP positive immunohistochemical staining in
scaffolds initially seeded with transduced cells (Fig. 5B, left plots);
Figure 2. Functional evaluation of hsRL produced by transduced HEK293T cells. Osteoclastogenesis and resorption assays from (A)
human PBMCs and (B) murine WT and Rankl−/− splenocytes in the presence of M-CSF and ×50 concentrated conditioned medium from
mock-transduced and LVhsRL-transduced HEK293T cells (left and right plots, respectively). Mature osteoclasts were identiﬁed by TRAP
staining, while resorption pits were visualized by staining dentin discs with toluidine blue. Scale bars: 200 μm (A); 400 μm (B).
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it could be reasonably inferred, even though we have not for-
mally proven, that the same will have occurred in WT MSC-
seeded scaffolds. In addition, a large number of cells found on
the scaffolds were represented by F4/80+ macrophages from the
host (Supporting Information Fig. S1).
Next, we assessed whether the implanted cell-scaffold con-
structs affected the skeletal phenotype of Rankl−/− mice. TRAP
staining revealed the presence of TRAP+ cells speciﬁcally in the
bone of Rankl−/− mice implanted with a WT or LVhsRL-
transduced Rankl−/− MSC-seeded scaffold, while no TRAP+ cells
were found in Rankl−/− mice implanted with a mock-transduced
Rankl−/− MSC-seeded scaffold (Fig. 6A, left plots, and 6B), in
accordance with previous reports on the absence of TRAP+ cells
in the Rankl−/− mouse model [9]. This suggests that the hsRL
molecule secreted by WT and LVhsRL-transduced Rankl−/− MSCs
can induce to a certain extent formation of TRAP+ cells, which
could be reasonably regarded as cells of the osteoclast lineage.
To enhance the effect at the cellular level, we performed
another group of experiments, in which 1.5 × 106 cells where
seeded on each scaffold, with a seeding efﬁciency of about 80%,
and 2 scaffolds were implanted in each Rankl−/− mouse; after sac-
riﬁce we carried out the same evaluations as above. Histological
analysis of the harvested cell-scaffold constructs showed abun-
dant vascularization and a more prominent presence of cells,
comprising also of GFP+ ones, as expected based on the higher
number of cells initially seeded (Fig. 5, right plots). Within the
bone tissue, we found a clear increase in TRAP+ cells in the bone
of Rankl−/− mice implanted with WT MSC-seeded scaffolds and
even more in those implanted with LVhsRL-transduced Rankl−/−
MSC-seeded scaffolds, as compared with mice of the same treat-
ment group with a single scaffold. On the other hand, TRAP+ cells
were still completely absent in the control group (i.e., Rankl−/−
mice plus mock-transduced Rankl−/− MSC-seeded scaffolds), as
expected (Fig. 6A, right plots, and 6B). Serological analysis of
Figure 3. Characterization of 3D biomimetic MgHA/Col scaffold. (A) Scanning Electron Microscopy micrographs at different magniﬁca-
tions, showing scaffold porosity and micro-architectures of the hybrid composite. (B) Porosity and chemical composition of the hybrid
MgHA/Col scaffold. (C) TGA, (D) FTIR, and (E) XRD analysis. In plots D and E, the solid line indicates the MgHA/Col, while the dashed one
the HA. (F) Evaluation of the swelling ratio and (G) percentage of degradation of MgHA/Col scaffolds overtime.
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bone-related parameters showed a signiﬁcant increase of total
calcium in mice implanted with WT-transduced and LVhsRL-
transduced Rankl−/− MSC-seeded scaffolds, even though physio-
logical levels were not reached (Fig. 6C). Nonetheless, indepen-
dent of the type of implanted construct, the classic osteopetrotic
features were still present in the treated Rankl−/− mice, as shown
by H&E staining: bone was very dense, with cartilage remnants,
and no clear evidence of remodeling and very few marrow cells
(Fig. 7). Accordingly, no difference was found in serum TRAP
activity among the groups (data not shown).
We also evaluated whether the in vivo implantation of
these constructs, and in particular the continuous release of
hsRL by LVhsRL-transduced cells, caused any side effect. At sac-
riﬁce, no gross abnormality potentially related to the performed
procedure was observed, nor were pathological signs found by
standard histological analysis of selected organs, including liver,
kidney, and lung (Supporting Information Fig. S2).
DISCUSSION
The combination of biomaterials mimicking bone extracellular
matrix and MSCs or engineered MSCs is a valid option for
regenerative medicine and for cell-based tissue engineering
therapies [32].
In particular, MSCs might serve as long-lasting reservoir of
biologically active compounds [33, 34].
Accordingly, here we used a biocompatible hybrid scaffold
composed of type I collagen and Magnesium-doped HA,
seeded with either murine WT or Rankl−/− MSCs-transduced
with a lentiviral vector restoring RANKL production, and
implanted in Rankl−/− mice, to provide mice the missing essen-
tial osteoclastogenic factor. A scaffold with the same composi-
tion had been already used and reported to support in vivo
MSC osteogenic differentiation [13, 35]. In the present work,
this composite was produced through an ad hoc modiﬁed pro-
cedure that allowed achieving features of natural bone on the
mandatorily reduced scale (i.e., the same size as the well of a
96-well plate) required by the small size of Rankl−/− mice [9].
Cross-linked collagen type I ﬁbrils, the main component of the
osteoid in vivo, served as templates onto which the inorganic
elements settled, thus forming a mineralized bone matrix. The
presence of Mg2+ ions inside the nucleated HA lattice and the
chemical interaction between the mineral and the organic phase
constrained the nucleation of apatite and reduced its crystallin-
ity. These features made the obtained hybrid highly biomimetic,
especially with respect toyoung and immature bone, and
favored its biological properties. In fact, previous studies [2, 13,
35] and the present work demonstrated that this kind of scaffold
Figure 4. Characterization of MSC culture on MgHA/Col scaffolds. (A) Confocal analysis of LVhsRL-transduced Rankl−/− MSC-seeded scaf-
folds at different time points; blue color corresponds to collagen ﬁbers, green to MSCs. Scale bar: 200 μm (B) Assessment of WT, mock-
transduced and LVhsRL-transduced Rankl−/− MSC proliferation in 2D versus 3D culture overtime by MTT assay. Cell growth is expressed as
fold increase compared to time 0. Statistics is referred to comparison of 2D versus 3D for each group. Cell growth fold increase
data  SEM are reported in Supporting Information Table 1. (C) Evaluation of hsRL concentration in the supernatant of LVhsRL-
transduced Rankl−/− MSCs in 2D versus 3D culture by ELISA assay. *p < .05; **p < .01.
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was bioactive, biodegradable, biocompatible, and easily recog-
nized by cells, thanks to the high hydrophilicity and porosity, par-
ticularly in terms of macropores, which fostered cell adhesion,
colonization, proliferation, and RANKL cytokine production, in
agreement with reports in literature referring to different con-
texts [36, 37]. Moreover, once implanted subcutaneously in
mice, these scaffolds were extensively vascularized; in line with
other ﬁndings [38, 39], this should have favored graft-host inter-
action and MSCs survival, and supported the systemic distribu-
tion of soluble factors, likely comprising also RANKL, produced
by the implanted cells.
Another strength of our approach is the optimization of
murine MSC transduction with a lentiviral vector establishing
continuous production of human soluble RANKL [13], which
promoted osteoclastogenesis in vitro. Implantation of cell-
seeded scaffolds in Rankl−/− mice led to TRAP+ cells formation
in knock-out mice receiving the implant of a single LVhsRL-
producing cell construct, indicating that the released cytokine
was functional in vivo, too. In parallel, a similar result was not
observed either in vitro or in vivo in the presence of mock-
transduced Rankl−/− MSCs, further proving that the biological
response elicited was dependent on the RANKL molecule
expressed by the viral vector. We could not formally demon-
strate the presence of hsRL in the sera of Rankl−/− mice
implanted with LVhsRL-expressing constructs, but this was not
surprising, as in other experimental settings a short half-life of
exogenous RANKL in the circulation has been reported [9, 27].
No major side effect of these implants was observed over
the 2 month follow-up period or at necropsy, indicating that
this treatment was safe. On the other hand, the biological
effect attained in Rankl−/− mice was limited and no ameliora-
tion of the osteopetrotic phenotype was observed. These
results prompted us to conceive a strategy that could possibly
enhance the beneﬁt gained on the skeletal tissue of Rankl−/−
mice by increasing the amount of cytokine delivered in vivo.
To reach this goal, we increased the number of cells seeded
on each scaffold and the number of cell constructs implanted
in each mouse, even though no more than two of them could
be inserted in the subcutaneous pouch on the back of Rankl−/−
mice because of their severe growth retardation [9]. These
changes to the protocol led to an increase in TRAP+ cell forma-
tion in the bones of Rankl−/− mice receiving RANKL-producing
cell constructs, but again the skeletal defect was not improved.
Thus, at present the pharmacological administration of soluble
Figure 5. Histological analysis of MSC-seeded MgHA/Col scaffolds after 2 months implantation in Rankl−/− mice. (A) Hematoxylin–Eosin
staining and CD31 immunostaining on serial sections of decalciﬁed scaffolds from the different groups of treatment. Scale bar: 100 μm.
(B) GFP immunostaining on sections of decalciﬁed scaffolds from the different groups of treatment. Scale bar: 50 μm.
© 2018 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
STEM CELLS TRANSLATIONAL MEDICINE
10 MSC-Seeded Scaffolds for RANKL Delivery
RANKL appears to be the most effective treatment for RANKL
ARO [9, 10]. Possible reasons for the failure of the approach
herein described to correct the ARO-phenotype of Rankl−/− mice
could be the limited amount of cytokine produced by WT and
LVhsRL-transduced Rankl−/−MSCs [13]; in the latter case, this was
dependent on the used MOI. Another possible explanation could
be the extensive colonization of the scaffold by immune cells of
the host, in particular a high number of macrophages, which
might have eliminated a signiﬁcant fraction of the cells originally
seeded [40]. More substantial modiﬁcations of the protocol, than
those used in the present study, would be necessary to improve
the outcome of this approach. For example, we might consider
increasing hsRL production by transduced cells, by using a higher
MOI; using telomerase overexpression in LVhsRL-transduced
Rankl−/− MSCs to augment their proliferation [41]; implanting a
higher number of scaffolds or larger scaffolds (as far as this is
technically feasible in these small mice); using a biomimetic smart
scaffold functionalized to enhanceMSC attachment [42]; isolating
the system from the host cells by means of newly developed cell
encapsulation systems, thus preventing its disruption [43]. The
optimization of these aspects might be pursued, for example, by
exploiting the emerging technology of rechargeable devices con-
taining 3D printed cell-seeded functionalized scaffolds [44], which
has already achieved promising results in other ﬁelds. Thus, the
integration of the strengths of our strategy with these new tools
will likely achieve a net improvement.
Figure 6. Evaluation of the effect of cell-constructs implantation on the bone phenotype of Rankl−/− mice. (A) TRAP staining on long
bone of Rankl−/− mice belonging to the different treatment groups. Scale bars: 50 μm (left); 20 μm (right). (B) Number of TRAP+ cells per
bone section of treated Rankl−/− mice. nd: not detected. (C) Measurement of serum total calcium concentration in treated Rankl−/− mice.
The red dashed line indicates the average concentration in age matched wild type mice. *p < .05.
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CONCLUSION
In this work, we have utilized a lentiviral vector for the stable
expression of hsRL, which sustained in vitro human and mouse
osteoclast differentiation. We have transduced Rankl−/− MSCs
and set up conditions for their 3D culture on an MgHA/Col
biomimetic scaffold. In particular, the chemical and physical
properties of this scaffold enhanced MSC proliferation and
hsRL production. After implantation of these MSC-seeded con-
structs in Rankl−/− mice, TRAP+ cells formed in bone, thus pro-
viding proof of principle of the capacity of this approach to
support cell differentiation towards the osteoclast lineage
in vivo. Optimization of the experimental setting exploiting
also the most recent biotechnological tools will increase the
efﬁcacy of this strategy on the bone compartment. As a per-
spective, we might pursue further implementation of this sys-
tem using patients-derived cells for a future possible
autologous cell and gene therapy approach.
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